CD46 and Oncologic Interactions: Friendly Fire against Cancer.

Area of Science:

• Oncology
• Immunology
• Virology

Background:

• CD46 (membrane cofactor protein; MCP) is a complement regulator expressed on most cells.
• CD46 is significantly overexpressed in various human tumors, correlating with malignant transformation and metastasis.
• CD46 also regulates metabolic processes and intracellular complement, acting as a receptor for microbes.

Purpose of the Study:

• To review the oncologic connections of CD46.
• To highlight CD46's role in cancer progression and therapeutic targeting.
• To discuss current clinical trials investigating CD46-targeted therapies.

Main Methods:

• Literature review of studies on CD46 in cancer.
• Analysis of clinical and experimental data linking CD46 expression to malignancy.
• Examination of therapeutic strategies utilizing CD46 as a target.

Main Results:

• CD46 overexpression is associated with increased malignant transformation and metastatic potential.
• CD46 drives metabolic processes and is involved in the intracellular complement system.
• Oncolytic viruses (measles, adenoviruses) and antibody-drug conjugates targeting CD46 are in clinical development.

Conclusions:

• CD46 is a critical target in cancer therapeutics due to its role in malignancy.
• Multiple clinical trials are evaluating CD46-targeted therapies for various cancers.
• Targeting CD46 represents a promising strategy for novel cancer treatments.